Trial Profile
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 06 Nov 2019 Results evaluating the safety and efficacy of using lenalidomide and ixazomib as part of consolidation and maintenance therapies after ASCT presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 19 Sep 2019 Planned primary completion date changed from 30 Nov 2019 to 1 Feb 2020.
- 19 Sep 2019 Status changed from recruiting to active, no longer recruiting.